What a tremendous job you all have done on this project! The work is detailed, thorough and systematic . . .with ‘out of the box’ thinking.
Payer & Channel Insights, Marketing Analytics & Business Insights
The staff loved the program and I ordered a booklet on each topic through your portal. The nurses were able to take notes while following along and not one was left behind.
[Large IDN] is extremely interested in the various topics and we are working to customize the programs for their account. The entire staff is expected to attend two speaker programs throughout the year. We are partnering with them to ensure success and educate their staff – and ultimately to provide the best patient care. This program has provided us with a valuable resource and I highly encourage my teammates to take advantage of the opportunity.
NorthEastern Region, Top 20 Pharma
Thank you so much for reaching out to me. I have heard rave reviews about your presentation on Oncology Nurse Navigation.
You did a terrific job with the market access training, and I’m actually looking forward to the next phase (and that is straight talk). Once I got over complaining that I had to do it and then complaining that I couldn’t fast forward through the slides, I focused on the content which was comprehensive, relevant and valuable. So, thank you both for leading this important initiative!
Executive Team Lead
Top 5 Pharma
The 3 educational payer modules were outstanding. The team did an excellent job in pulling together the content. We should do this on an ongoing basis. Again – great job!!!
Very professional and well laid out training course! Well done identifying the need to deepen our team’s knowledge on this topic. The content was highly relevant and helped put into context so many issues that we deal with in our jobs. Bottom line: Excellent.
Sr. Marketing Director
Top 10 Pharma
Your Payer Acumen training was really well done -- one of the better online courses I have taken. Can I get a copy for future reference and to use with field sales?
Top 5 Pharma
responsiveness throughout the Market Access training process. Your follow-up on a range of issues was always immediate and the resolution was definitive. That type of effort and support doesn’t go unnoticed by me.
Just a quick note of appreciation for your
National Business Director
Top 5 Pharma
We have never seen a diagnostic like this before – it gets right to the heart of the problem.
Specialty Access Solutions, Top 5 Pharma
The insights you provided via Hub Excellence were the most insightful and actionable market research I have ever received.
Director of Operations
Reimbursement and Patient Support Services, Top 20 Pharma
RxScorecard provides a comprehensive, multi-pronged rubric assisting us in decision-making as we begin to move from a volume to value drug evaluation methodology.
Chronis H. Manolis, RPh
Vice President, Pharmacy UPMC Health Plan
RxScorecard lets a biopharma company anticipate the most important factors impacting the clinical & economic value of pipeline and marketed drugs -- and then helps identify the necessary changes to the clinical development and commercial program to maximize that value for all stakeholders, especially including payers. It's a required, straightforward, objective strategic tool that allows us to quickly and effectively adapt to a rapidly changing and much more challenging market access environment.
Global Value/Market Access Lead Oncology Portfolio & Global Commercial Lead Oncology Biomarkers Halozyme Therapeutics, Inc.
We at GSK believe that it’s critical for the pharmaceutical industry to produce drugs that deliver value for patients, providers and payers. We have found RxScorecard to be an insightful framework for assessing and comparing the value of drugs, both marketed and developmental assets. The perspective it provides supports improved customer-focused development and commercialization, and we and our customers can benefit from its use.
President , GlaxoSmithKline U.S.
With pharmacy costs increasing so quickly, there is increasing pressure for P&T and Technology Assessment Committees to consider the value as well as the clinical efficacy of the drugs under evaluation. By providing an objective framework for assessing value, RxScorecard fills a gap in the existing toolkit available to health plans. And with greater discussion around narrower formularies, RxScorecard becomes even more important.
Michael S. Sherman, MD, MBA
Senior Vice President and Chief Medical Officer, Harvard Pilgrim Health Care